Switching Between Reference Biologics and Biosimilars for the Treatment of Rheumatology, Gastroenterology, and Dermatology Inflammatory Conditions: Considerations for the Clinician.

Moots, Robert ORCID: 0000-0001-7019-6211, Azevedo, Valderilio, Coindreau, Javier L, Dörner, Thomas, Mahgoub, Ehab, Mysler, Eduardo, Scheinberg, Morton and Marshall, Lisa (2017) Switching Between Reference Biologics and Biosimilars for the Treatment of Rheumatology, Gastroenterology, and Dermatology Inflammatory Conditions: Considerations for the Clinician. Current rheumatology reports, 19 (6). 37-.

Access the full-text of this item by clicking on the Open Access link.

Official URL: http://dx.doi.org/10.1007/s11926-017-0658-4

Abstract

<h4>Purpose of review</h4>Biosimilars of the reference biologic therapeutics infliximab, etanercept, adalimumab, and rituximab are entering the market. Clinical and real-world data on the effects of reference → biosimilar switching are limited. This review was carried out to assess the current body of switching data.<h4>Recent findings</h4>Fifty-three switching studies were identified. Infliximab publications covered CT-P13 (25 studies), SB2 (1), infliximab NK (1), and unspecified infliximab biosimilars (2). Etanercept publications covered SB4 (2) and GP2015 (2). Adalimumab publications covered ABP 501 (2) and SB5 (1). Rituximab publications covered CT-P10 (1). Efficacy and safety data generally showed no differences between patients who switched treatments versus those who did not. No differences were seen pre- and post-switch. Immunogenicity data were presented in 19/37 (51%) studies. Additional data from switching studies of these therapies are still required, as is continuing pharma-covigilance. Switching should remain a case-by-case clinical decision made by the physician and patient on an individual basis supported by scientific evidence.

Item Type:	Article
Uncontrolled Keywords:	Humans, Rheumatic Diseases, Gastrointestinal Diseases, Skin Diseases, Antirheumatic Agents, Gastrointestinal Agents, Dermatologic Agents, Biological Products, Treatment Outcome, Drug Substitution, Biosimilar Pharmaceuticals
Depositing User:	Symplectic Admin
Date Deposited:	29 Jun 2017 10:10
Last Modified:	19 Jan 2023 07:02
DOI:	10.1007/s11926-017-0658-4
Open Access URL:	https://link.springer.com/article/10.1007/s11926-0...
Related URLs:	Author Publisher
URI:	https://livrepository.liverpool.ac.uk/id/eprint/3008191